Mallinckrodt Plc Ordinary Share (MNK) 74.55 $MNK
Allergan Takes Over RetroSense; Boosts Eye Care Pipeline
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:20AM CDT
Allergan plc (AGN) has acquired RetroSense Therapeutics, a privately held, clinical-stage biotechnology company, which will add the latter's lead gene therapy development program RST-001 to its eye care pipeline.
MNK: 74.55 (-0.37), AGN: 238.42 (-0.70), AXGN: 9.00 (+0.06), AMPH: 19.03 (+0.12)
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PR Newswire - Wed Aug 31, 4:00PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced it closed the acquisition of Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft® regenerative skin tissue and a technology platform for genetically enhanced skin tissues.
MNK: 74.55 (-0.37)
Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 74.55 (-0.37), TSLA: 201.71 (-1.12), ENDP: 20.30 (-0.19), F: 12.70 (+0.03), MDT: 86.15 (-1.02), GME: 28.13 (-0.24), MYL: 40.31 (-0.09), PDCO: 47.18 (+0.18), TIF: 69.78 (+0.61), BA: 132.64 (-0.35), ESRX: 72.67 (-0.05), STJ: 79.18 (+0.28), SSYS: 21.97 (-0.79), TECD: 73.62 (+0.78), ADSK: 68.60 (+0.91)
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.55 (-0.37), CATB: 4.30 (-0.57), ANIP: 60.71 (-0.84), SRPT: 28.46 (+0.67)
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 74.55 (-0.37), MDCO: 37.38 (-0.86), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25)
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND Application
PR Newswire - Thu Aug 25, 6:30AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted the company's request for a Fast Track designation for its Investigational New Drug (IND) application for Synacthen® Depot in the treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.
MNK: 74.55 (-0.37)
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million
PR Newswire - Wed Aug 24, 7:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM), for approximately $690 million before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations.
MNK: 74.55 (-0.37)
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs
PR Newswire - Tue Aug 23, 7:00AM CDT
Approval granted for reimbursement of Extracorporeal Photopheresis (ECP) for Bronchiolitis Obliterans Syndrome (BOS) derived from lung transplantation.
MNK: 74.55 (-0.37)
Mallinckrodt To Present At Morgan Stanley Global Healthcare Conference
PR Newswire - Mon Aug 22, 6:30AM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Sept. 12, 2016, at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York, 109 E. 42nd St., New York.
MNK: 74.55 (-0.37), MS: 31.69 (-0.06)
Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment
PR Newswire - Thu Aug 18, 6:55AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today it will build out a new campus for its fast-growing Specialty Brands organizations in the Somerset Financial Center, 1405-1425 Route 206, in Bedminster. Mallinckrodt will invest greater than $80 million in New Jersey, and anticipates approximately 400 employees will occupy the new space in the first quarter of 2017.
MNK: 74.55 (-0.37)
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 11:24AM CDT
Mallinckrodt plc (MNK) announced that it will acquire privately held regenerative medicine company, Stratatech Corporation.
MNK: 74.55 (-0.37), MDCO: 37.38 (-0.86), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25)
Blog Coverage Mallinckrodt Acquires Privately Held Regenerative Skin Technology Firm
ACCESSWIRE - Fri Aug 12, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 12, 2016 / Active Wall St. blog coverage looks at the headline from Mallinckrodt PLC (NYSE: MNK) as the company announced on August 10, 2016, that it has entered into an agreement with Stratatech Corp. to acquire the company which specializes in the manufacture of regenerative skin and skin substitute products. The financial details were not disclosed at the time of announcement and the deal is expected to close in the second half of 2016. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
MNK: 74.55 (-0.37)
Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PR Newswire - Wed Aug 10, 4:45PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.
MNK: 74.55 (-0.37)
Gilead Sciences, Williams Companies, Procter & Gamble, Mallinckrodt Public Limited Company, and Western Digital and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, MNK, PG, WDC, and WMB.
MNK: 74.55 (-0.37), GILD: 78.22 (+0.34), WMB: 30.34 (+1.18), PG: 87.95 (-0.69), WDC: 53.30 (+5.75)
Mallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:51PM CDT
Mallinckrodt plc (MNK) reported adjusted earnings of $2.20 per share in the third quarter of fiscal 2016 (ended Jun 24, 2016), beating the Zacks Consensus Estimate of $2.01.
MNK: 74.55 (-0.37), IPXL: 24.47 (+0.23), SUPN: 22.51 (+0.32), MYL: 40.31 (-0.09)
Royal Caribbean and General Motors fall; CVS advances
AP - Tue Aug 02, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MNK: 74.55 (-0.37), DISCK: 24.44 (-0.03), F: 12.70 (+0.03), DAL: 38.90 (+2.08), PFE: 34.84 (+0.07), STX: 36.51 (+2.04), DISCB: 27.25 (+0.05), DISCA: 25.07 (-0.02), CVS: 93.61 (+0.25), GM: 31.89 (-0.23)
Mallinckrodt (MNK) Tops on Earnings & Sales in Q3
Ekta Bagri - Zacks Investment Research - Tue Aug 02, 5:48AM CDT
Mallinckrodt beat on earnings by a wide margin. Our consensus called for EPS of $2.01, and the company reported EPS of $2.20.
MNK: 74.55 (-0.37)
Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016
PR Newswire - Tue Aug 02, 5:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the third quarter of fiscal 20161. Unless otherwise noted, all comparisons of fiscal 2016 third quarter or year-to-date performance are to the comparable periods of fiscal 2015.
MNK: 74.55 (-0.37)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.55 (-0.37), BIIB: 312.30 (+1.63), ABT: 41.90 (-0.26), JNJ: 119.61 (-0.14), GILD: 78.22 (+0.34), MRK: 62.87 (-0.37), PFE: 34.84 (+0.07), SGNT: 21.76 (+0.03), ABBV: 64.97 (+0.36), PRTA: 55.33 (+0.82), NVS: 80.36 (+0.21)
Allergan Takes Over RetroSense; Boosts Eye Care Pipeline
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:20AM CDT
Allergan plc (AGN) has acquired RetroSense Therapeutics, a privately held, clinical-stage biotechnology company, which will add the latter's lead gene therapy development program RST-001 to its eye care pipeline.
MNK: 74.55 (-0.37), AGN: 238.42 (-0.70), AXGN: 9.00 (+0.06), AMPH: 19.03 (+0.12)
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PR Newswire - Wed Aug 31, 4:00PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced it closed the acquisition of Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft® regenerative skin tissue and a technology platform for genetically enhanced skin tissues.
MNK: 74.55 (-0.37)
Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 74.55 (-0.37), TSLA: 201.71 (-1.12), ENDP: 20.30 (-0.19), F: 12.70 (+0.03), MDT: 86.15 (-1.02), GME: 28.13 (-0.24), MYL: 40.31 (-0.09), PDCO: 47.18 (+0.18), TIF: 69.78 (+0.61), BA: 132.64 (-0.35), ESRX: 72.67 (-0.05), STJ: 79.18 (+0.28), SSYS: 21.97 (-0.79), TECD: 73.62 (+0.78), ADSK: 68.60 (+0.91)
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.55 (-0.37), CATB: 4.30 (-0.57), ANIP: 60.71 (-0.84), SRPT: 28.46 (+0.67)
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 74.55 (-0.37), MDCO: 37.38 (-0.86), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25)
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND Application
PR Newswire - Thu Aug 25, 6:30AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted the company's request for a Fast Track designation for its Investigational New Drug (IND) application for Synacthen® Depot in the treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.
MNK: 74.55 (-0.37)
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million
PR Newswire - Wed Aug 24, 7:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM), for approximately $690 million before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations.
MNK: 74.55 (-0.37)
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs
PR Newswire - Tue Aug 23, 7:00AM CDT
Approval granted for reimbursement of Extracorporeal Photopheresis (ECP) for Bronchiolitis Obliterans Syndrome (BOS) derived from lung transplantation.
MNK: 74.55 (-0.37)
Mallinckrodt To Present At Morgan Stanley Global Healthcare Conference
PR Newswire - Mon Aug 22, 6:30AM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Sept. 12, 2016, at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York, 109 E. 42nd St., New York.
MNK: 74.55 (-0.37), MS: 31.69 (-0.06)
Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment
PR Newswire - Thu Aug 18, 6:55AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today it will build out a new campus for its fast-growing Specialty Brands organizations in the Somerset Financial Center, 1405-1425 Route 206, in Bedminster. Mallinckrodt will invest greater than $80 million in New Jersey, and anticipates approximately 400 employees will occupy the new space in the first quarter of 2017.
MNK: 74.55 (-0.37)
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 11:24AM CDT
Mallinckrodt plc (MNK) announced that it will acquire privately held regenerative medicine company, Stratatech Corporation.
MNK: 74.55 (-0.37), MDCO: 37.38 (-0.86), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25)
Blog Coverage Mallinckrodt Acquires Privately Held Regenerative Skin Technology Firm
ACCESSWIRE - Fri Aug 12, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 12, 2016 / Active Wall St. blog coverage looks at the headline from Mallinckrodt PLC (NYSE: MNK) as the company announced on August 10, 2016, that it has entered into an agreement with Stratatech Corp. to acquire the company which specializes in the manufacture of regenerative skin and skin substitute products. The financial details were not disclosed at the time of announcement and the deal is expected to close in the second half of 2016. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
MNK: 74.55 (-0.37)
Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PR Newswire - Wed Aug 10, 4:45PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.
MNK: 74.55 (-0.37)
Gilead Sciences, Williams Companies, Procter & Gamble, Mallinckrodt Public Limited Company, and Western Digital and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, MNK, PG, WDC, and WMB.
MNK: 74.55 (-0.37), GILD: 78.22 (+0.34), WMB: 30.34 (+1.18), PG: 87.95 (-0.69), WDC: 53.30 (+5.75)
Mallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:51PM CDT
Mallinckrodt plc (MNK) reported adjusted earnings of $2.20 per share in the third quarter of fiscal 2016 (ended Jun 24, 2016), beating the Zacks Consensus Estimate of $2.01.
MNK: 74.55 (-0.37), IPXL: 24.47 (+0.23), SUPN: 22.51 (+0.32), MYL: 40.31 (-0.09)
Royal Caribbean and General Motors fall; CVS advances
AP - Tue Aug 02, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MNK: 74.55 (-0.37), DISCK: 24.44 (-0.03), F: 12.70 (+0.03), DAL: 38.90 (+2.08), PFE: 34.84 (+0.07), STX: 36.51 (+2.04), DISCB: 27.25 (+0.05), DISCA: 25.07 (-0.02), CVS: 93.61 (+0.25), GM: 31.89 (-0.23)
Mallinckrodt (MNK) Tops on Earnings & Sales in Q3
Ekta Bagri - Zacks Investment Research - Tue Aug 02, 5:48AM CDT
Mallinckrodt beat on earnings by a wide margin. Our consensus called for EPS of $2.01, and the company reported EPS of $2.20.
MNK: 74.55 (-0.37)
Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016
PR Newswire - Tue Aug 02, 5:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the third quarter of fiscal 20161. Unless otherwise noted, all comparisons of fiscal 2016 third quarter or year-to-date performance are to the comparable periods of fiscal 2015.
MNK: 74.55 (-0.37)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.55 (-0.37), BIIB: 312.30 (+1.63), ABT: 41.90 (-0.26), JNJ: 119.61 (-0.14), GILD: 78.22 (+0.34), MRK: 62.87 (-0.37), PFE: 34.84 (+0.07), SGNT: 21.76 (+0.03), ABBV: 64.97 (+0.36), PRTA: 55.33 (+0.82), NVS: 80.36 (+0.21)
